Cargando…

Hemorrhagic corpus luteum: Clinical management update

Hemorrhagic corpus luteum (HCL) is an ovarian cyst formed after ovulation and caused by spontaneous bleeding into a corpus luteum (CL) cyst. When HCL rupture happens, a hemoperitoneum results. Clinical symptoms are mainly due to peritoneal irritation by the blood effusion. The differential diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Medvediev, Mykhailo V, Malvasi, Antonio, Gustapane, Sarah, Tinelli, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731611/
https://www.ncbi.nlm.nih.gov/pubmed/33343977
http://dx.doi.org/10.4274/tjod.galenos.2020.40359
_version_ 1783621934317043712
author Medvediev, Mykhailo V
Malvasi, Antonio
Gustapane, Sarah
Tinelli, Andrea
author_facet Medvediev, Mykhailo V
Malvasi, Antonio
Gustapane, Sarah
Tinelli, Andrea
author_sort Medvediev, Mykhailo V
collection PubMed
description Hemorrhagic corpus luteum (HCL) is an ovarian cyst formed after ovulation and caused by spontaneous bleeding into a corpus luteum (CL) cyst. When HCL rupture happens, a hemoperitoneum results. Clinical symptoms are mainly due to peritoneal irritation by the blood effusion. The differential diagnosis is extensive and standard management is not defined. The authors elaborated a comparison of the differential diagnosis and therapeutic modalities from the laparoscopic approach to nonsurgical, medical options because hemorrhage from HCL is often self-limiting. The authors reviewed all data implicated with the development of HCL, trying to give homogeneity to literature data. The authors analyzed extensive literature data and subdivided the medical approach into many topics. The wait-and-see attitude avoids unnecessary laparoscopic surgery using supportive therapies (antifibrinolytic, analgesics, liquid infusion, transfusions and antibiotic prophylaxis). Surgical therapy: operative management should be laparoscopic, with surgical options such as luteumectomy, ovarian wedge-shaped excision or oophorectomy. Prevention: the possibility to preserve fertility is essential, mainly in patients with bleeding disorders or undergoing anticoagulant therapy; therefore, they need estro-progestinics or GnRH analogues to prevent ovulation and avoid further episodes of HCL. This review will aid physicians in making an early diagnosis of HCL, to avoid unnecessary surgery, and use the most effective treatment.
format Online
Article
Text
id pubmed-7731611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-77316112020-12-18 Hemorrhagic corpus luteum: Clinical management update Medvediev, Mykhailo V Malvasi, Antonio Gustapane, Sarah Tinelli, Andrea Turk J Obstet Gynecol Review Hemorrhagic corpus luteum (HCL) is an ovarian cyst formed after ovulation and caused by spontaneous bleeding into a corpus luteum (CL) cyst. When HCL rupture happens, a hemoperitoneum results. Clinical symptoms are mainly due to peritoneal irritation by the blood effusion. The differential diagnosis is extensive and standard management is not defined. The authors elaborated a comparison of the differential diagnosis and therapeutic modalities from the laparoscopic approach to nonsurgical, medical options because hemorrhage from HCL is often self-limiting. The authors reviewed all data implicated with the development of HCL, trying to give homogeneity to literature data. The authors analyzed extensive literature data and subdivided the medical approach into many topics. The wait-and-see attitude avoids unnecessary laparoscopic surgery using supportive therapies (antifibrinolytic, analgesics, liquid infusion, transfusions and antibiotic prophylaxis). Surgical therapy: operative management should be laparoscopic, with surgical options such as luteumectomy, ovarian wedge-shaped excision or oophorectomy. Prevention: the possibility to preserve fertility is essential, mainly in patients with bleeding disorders or undergoing anticoagulant therapy; therefore, they need estro-progestinics or GnRH analogues to prevent ovulation and avoid further episodes of HCL. This review will aid physicians in making an early diagnosis of HCL, to avoid unnecessary surgery, and use the most effective treatment. Galenos Publishing 2020-12 2020-12-10 /pmc/articles/PMC7731611/ /pubmed/33343977 http://dx.doi.org/10.4274/tjod.galenos.2020.40359 Text en ©Copyright 2020 by Turkish Society of Obstetrics and Gynecology | Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Medvediev, Mykhailo V
Malvasi, Antonio
Gustapane, Sarah
Tinelli, Andrea
Hemorrhagic corpus luteum: Clinical management update
title Hemorrhagic corpus luteum: Clinical management update
title_full Hemorrhagic corpus luteum: Clinical management update
title_fullStr Hemorrhagic corpus luteum: Clinical management update
title_full_unstemmed Hemorrhagic corpus luteum: Clinical management update
title_short Hemorrhagic corpus luteum: Clinical management update
title_sort hemorrhagic corpus luteum: clinical management update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731611/
https://www.ncbi.nlm.nih.gov/pubmed/33343977
http://dx.doi.org/10.4274/tjod.galenos.2020.40359
work_keys_str_mv AT medvedievmykhailov hemorrhagiccorpusluteumclinicalmanagementupdate
AT malvasiantonio hemorrhagiccorpusluteumclinicalmanagementupdate
AT gustapanesarah hemorrhagiccorpusluteumclinicalmanagementupdate
AT tinelliandrea hemorrhagiccorpusluteumclinicalmanagementupdate